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Abstract
Background—Most studies point to a direct association between social support and better 
cancer outcomes. This study examined whether baseline social support is associated with better 
survival and fewer chemotherapy-related adverse events in older, early-stage breast cancer 
patients.
Methods—This study is part of a pre-planned secondary analysis of CALGB 49907/Alliance 
A171301, a randomized trial that compared standard adjuvant chemotherapy versus capecitabine 
in breast cancer patients 65 years of age or older. A subset of patients reported on the extent of 
their social support.
Results—The median age of this 331-patient cohort was 72 years (range: 65, 90); 179 (55%) 
were married, and 210 (65%) lived with someone. 145 patients (46%) described a social network 
of 0-10 people; 110 (35%) of 11-25; and 58 (19%) of 26 or more. The Medical Outcomes Study 
(MOS) social support survey revealed the median scores (range) for emotional/informational, 
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tangible, positive social interaction, and affectionate social support were 94 (3, 100), 94 (0, 100), 
96 (0, 100), and 100 (8, 100), respectively. Social support scores appeared stable over time and 
higher (more support) than in other cancer settings. No statistically significant associations were 
observed between social support and the outcomes of survival and adverse events in multivariate 
analyses. However, married patients had smaller tumors, and those with arthritis reported less 
social support.
Conclusion—Although social support did not predict survival and adverse events, the 
exploratory but plausible inverse associations with larger tumors and arthritis suggest social 
support merits further study in older breast cancer patients.
Introduction
Most published studies point to a direct association between robust social support and 
improved cancer outcomes, such as more favorable survival and better quality of life [1-4]. 
Social support is commonly defined as a network of close relatives and friends who can 
potentially help a cancer patient during illness [5]. In older patients, this support is of value 
because it helps compensate for the many losses -- loss of spouse/partner, loss of friends, 
loss of siblings, among others -- that occur at an accelerated pace once individuals have 
reached an older age. Social support likely enables older cancer patients to attend clinic 
appointments, to undergo diagnostic testing, to arrive at the chemotherapy unit for cancer 
treatment, to feel emotionally sustained during cancer therapy, to receive timely surveillance 
following cancer treatment -- in effect, to procure all the needed benefits of optimal cancer 
care.
The reasons for the continued study of social support appear at least twofold. First, few 
previous studies have provided an in depth social support assessment that includes patient-
reported perceptions of social support as well as more detailed reporting of marital status, 
cohabitation status, and number of close friends and family members. Analyzing and 
reporting both patients' perceived and objective social support should help clarify 
discrepancies in the published literature on the relationship between social support and 
clinical outcomes, particularly in older cancer patients. Secondly, the published literature 
carries potential selection bias. Positive studies are more likely to be submitted for 
publication -- and to be published -- than negative ones [6]. The large number of positive 
published studies that speak to the advantages of social support might reflect nothing more 
than such bias. Thus, further studying social support in older cancer patients and reporting 
on study results regardless of their findings remains worthwhile.
The current study capitalized on a prospectively-conducted, randomized, adjuvant trial in 
older breast cancer patients (CALGB 49907/Alliance A171301). It sought to characterize 
social support within a cohort of older, early-stage breast cancer patients who received 
adjuvant chemotherapy. Specifically, the current study sought to test the following two 
hypotheses: 1) objective social support (that is, being married, living with someone, and/or 
having a large number of friends/family members) at the time of a breast cancer diagnosis 
has a favorable effect on survival and adverse events in patients 65 years of age or older and 
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This study is a secondary analysis of CALGB 49907/Alliance A171301, a previously-
reported clinical trial that examined adjuvant chemotherapy in early-stage breast cancer 
patients who were 65 years of age or older as part of a multi-site, National Cancer Institute-
funded, cancer cooperative group trial [7]. Briefly, patients were randomly assigned to either 
standard chemotherapy (cyclophosphamide/methotrexate/fluorouracil for 6 cycles or 
doxorubicin/cyclophosphamide for 4 cycles) versus capecitabine for 6 cycles. Patients 
participated in a clinic visit that included an adverse event assessment with the Common 
Terminology Criteria (CTC, version 2.0) on day 1 of each cycle of chemotherapy followed 
thereafter by clinic visits every 6 months for 2 years and then annually for 15 years after 
study entry.
The above trial included a preplanned quality of life substudy, as described in detail by 
Kornblith and others [8]. To enroll in the substudy, patients had to be English- or Spanish-
speaking with adequate cognitive and psychological function. Patients were consecutively 
approached after enrollment to the parent chemotherapy trial until a substudy sample size of 
350 eligible patients was reached.
Social Support Assessment
The study reported here explored the implications of social support in this cohort, focusing 
on patients who completed questions on objective social support as well as on the 
previously-validated, 20-item, Medical Outcome Study (MOS) Social Support Survey [9]. 
This questionnaire includes a 4-domain scale of social support: emotional/informational 
support, tangible support, positive social interaction support, and affectionate support. These 
domains are for the most part self-explanatory, particularly in the context of the actual 
survey questions [10]. Social support was graded with a 100-point scale with higher scores 
denoting the highest degree of social support. Patients were asked to complete the 
questionnaire at baseline, mid-chemotherapy, 1 month post-chemotherapy, and then at 12, 
18, and 24 months from their initial baseline assessment.
The MOS was especially advantageous because it not only includes 19 questions that 
captured patients' subjective feelings about social support but it also includes a question that 
allowed patients to report more objectively on the size of their social support network. This 
question was phrased, “About how many close friends and close relatives do you have now 
(people you feel at ease with and can talk to about what is on your mind)?” Furthermore, at 
study entry, patients were asked to complete two questions which also provided more 
objective measures of social support. One question was phrased, “What is your marital 
status?” with 5 choices that captured potential responses. The other was phrased, “With 
whom do you live?” and prompted patients to mark all that applied, including spouse/
partner, children aged 18 years or younger, parents/parents-in-law, other relative, live alone, 
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and other (specify). Thus, CALGB 49907/Alliance A171301 uniquely enabled patients to 
report on both subjective and objective measures of social support.
Data Analyses
Demographic and baseline social support data are presented descriptively. Because no 
salient differences in social support were observed among the treatment arms, all analyses 
were performed using the entire cohort. Comparative tests, as specified within each table, 
were used to examine associations between measures of social support and clinically 
relevant outcomes. Such analyses were adjusted for age when it was thought such clinical 
outcomes might vary at the extremes of the age spectrum. Relationships were explored 
between baseline social support (both objective and perceived) and other endpoints, such as 
overall survival, adverse events, and other exploratory endpoints of interest, such as patient 
morbidity. With respect to survival and subjective social support, MOS scores were 
dichotomized based on a perfect score of 100 versus any other score; a Cox proportional 
hazards model incorporated these dichotomized MOS scores along with study arm and 
tumor burden, which was characterized by tumor size and extent of lymph node 
involvement. A two-sided p-value of <0.05 is considered statistically significant. All 
analyses were performed with SAS, version 9 (Cary, North Carolina USA).
Results
Demographics
As noted, a total of 350 women were eligible for the quality of life, questionnaire portion of 
CALGB49907/Alliance A171301. Of these, 331 completed the baseline questionnaires of 
interest in this study and are the focus of this report. No demographic differences were 
observed between those who did and did not complete the social support questionnaires. The 
median age of this cohort was 72 years (range: 65, 90). Baseline demographics are 
summarized in Table 1.
Social Support
Objective measures showed that 179 patients (55%) were married. In response to the 
question, “With whom do you live?” 210 patients (65%) responded that they lived with at 
least one other person, and 115 (35%) lived alone (Table 1). The objective query on “close 
friends and close relatives” showed that the median size of patients' networks was 12 people 
(range: 0, 824). One hundred forty-five patients (46%) described a network that included 
0-10 people; 110 (35%) patients described 11-25 people; and 58 (19%) patients described 26 
or more people.
As per the MOS Social Support Questionnaire, patients reported that their baseline median 
(range) for the domains of emotional/informational, tangible, positive social interaction, and 
affectionate social support were 94 (3, 100), 94 (0, 100), 96 (0, 100), and 100 (8, 100), 
respectively (Table 1). Social support remained stable over time (Figure 1).
In an exploratory manner, we examined whether baseline social support was associated with 
tumor characteristics. Patients who were married had smaller tumors than those not married, 
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and, similarly, living alone was associated with a trend towards larger tumors (Table 2). In 
contrast, MOS scores were not associated with tumor size. No statistically significant 
associations were observed between lymph node tumor involvement and any of the social 
support variables (data not shown).
We also explored relationships between social support and certain categories of morbidity 
that we thought might potentially influence social support. We found no consistent 
associations with cognitive function, number of comorbid conditions, glaucoma, and 
circulatory issues (data not shown). However, patients with arthritis reported less social 
support across all four domains of the MOS compared to patients without arthritis with 
mean scores (standard deviations) of 82.4 (20.4) and 88.1 (17.5) for emotional/informational 
(p=0.006); 79.1 (23.8) and 87.7 (19.3) for tangible(p=0.0001); 81.4 (22.2) and 89.1 (17.8) 
for positive social interaction (p=0.0002); and 88.4 (19) and 92.7 (15.6) for affectionate 
(p=0.01), respectively.
Social Support, Survival, and Adverse Events
The median survival for the cohort has not yet been attained. At the time of this report, 107 
deaths had occurred. Although univariate analyses suggested that being married and not 
living alone were associated with better survival, in multivariate analyses, no statistically 
significant differences in survival were observed based on extent of social support, 
regardless of whether comparisons centered on size of support group, marital status, 
cohabitation status, or MOS score (Table 3).
Of note, 189 patients (57%) suffered one or more severe adverse events. However, no 
statistically significant relationships were observed between extent of social support and the 
development of severe adverse events (Table 4). Additionally, baseline social support, 
regardless of how it was assessed, was not significantly associated with whether a patient 
completed all her chemotherapy on protocol (data not shown).
Discussion
This study is one of many to examine the implications of social support in patients with 
cancer [1-4]. We sought to test the hypothesis that objective social support has a favorable 
effect on survival and adverse events in early-stage breast cancer patients 65 years of age or 
older and found this was not the case. We also sought to test whether older patients' greater 
perceived social support has a favorable impact on survival and adverse events and observed 
it does not.
In contrast to our findings, Lutgendorf and others examined 168 ovarian cancer patients, 
who admittedly were contending with a more advanced and lethal malignancy [2]. These 
investigators reported that a more robust subjective measure of social support, as assessed by 
means of patient-completed questionnaires, was associated with a lower likelihood of death 
[2]. Similarly, Deiperink and others examined 337 patients with T1-T3 prostate cancer and, 
although they did not report on adverse events, they did report on quality of life. They 
observed that, although cancer stage and dose of radiation had no impact on quality of life, 
patients who described living alone, an objective measure of social support, described 
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inferior quality of life [3]. To our knowledge, few prior studies have measured both objective 
and subjective social support. In our study, we found that neither demonstrated a statistically 
significant association with survival nor with adverse events from chemotherapy.
It remains unclear why so many other studies have identified an association between greater 
social support and better cancer outcomes and why this study did not. In addition to the 
explanations advanced earlier, another reason for this discrepancy is that the current study 
was a companion trial to a prospectively-conducted clinical trial in early-stage, potentially 
curable patients and may therefore have selected patients with a greater degree of baseline 
social support and better functional status. To be able to enroll in a clinical trial, to commit 
to extra testing (including extensive questionnaire completion), and to remain willing to 
participate in a well-defined plan of follow up post-chemotherapy is more likely to be 
possible in a cancer patient who has greater social support. Indeed, in the current study, the 
median size of a patient's network of people was 12, a number that seems substantial enough 
to be able to provide a patient the extra help she may need to participate in a clinical trial. 
Moreover, a recent study from Leung and others in breast cancer patients, who were not 
clinical trial participants, showed that the MOS questionnaire yielded overall lower social 
support scores within their cohort than what we observed in ours [11]. Thus, it seems 
possible that the overall high degree of social support in our cohort precluded our ability to 
discern major differences in clinical outcomes based on extent of social support, and it 
seems plausible that clinical trial participation selects for patients who have a higher degree 
of social support at baseline and who are healthier than the cancer population as a whole.
A second explanation for these absent associations may involve sample size. The sample 
size of the current study is relatively modest when compared to a few of the other studies 
that observed social support had a positive impact on cancer outcomes [1,4]. It is 
conceivable that the favorable impact of social support is subtle and that detecting this 
impact requires a much larger sample size than what was used in our analyses. These two 
explanations that social support might facilitate trial participation and that a large sample 
size might be necessary to detect the impact of social support are in fact interrelated and 
provide potential explanations for why the current study did not find that social support was 
associated with better cancer outcomes.
Yet a third explanation for the missing associations observed here may involve our 
multivariate analyses. Although we did observe some direct associations between social 
support and survival in univariate analyses – with patients living with someone or being 
married showing trends in favor of living longer –these associations lost their statistical 
significance in multivariate analyses. Thus, it is possible that many of the previous studies 
that observed notable direct relationships between social support and survival did not adjust 
for the same factors that we did.
Nonetheless, we do report three interesting observations. First, patients who were married 
were diagnosed with smaller breast tumors. This observation is the result of a post hoc 
exploratory analysis, but it appears plausible. Having a spouse does likely lead to patients' 
seeking healthcare more readily. Perhaps a spouse or cohabiting individual is more likely to 
urge a patient to seek healthcare sooner after the initial detection of a breast mass or perhaps 
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even to be more adherent to routine cancer screening. This last observation is in keeping 
with what others have reported on the relationship between social support and early cancer 
diagnosis [12,13]. Second, it also appears plausible that arthritis symptoms have a negative 
impact on social interactions because of compromised mobility, thereby restricting a 
patient's social support network. Indeed, in a recent analysis that examined the social 
implications of low back pain, Froud and others commented on how patients “struggle to 
meet social expectations and obligations” and on how some ultimately “withdraw” because 
of their inability to meet social demands [14]. Third, we observed stable social support over 
time per MOS scores. To our knowledge, this observation has not been previously reported, 
particularly over a long span of 2 years, as shown in our data. This observation might be 
viewed as reassuring within an older cohort who, with aging, appears more vulnerable for 
suffering from a decline in social support. Although these three observations were generated 
in an exploratory fashion, they seem noteworthy.
In conclusion, despite a lack of statistically significant findings with respect to our main 
endpoints, we believe there continues to be a strong impetus to study social support in older 
cancer patients, to understand the factors that contribute to social support, and to better 
understand its clinical implications in patients with a variety of cancer types. Our reported 
associations between social support and tumor size as well as arthritis symptoms suggest 
that the former can impact the health of older patients. Future studies should perhaps focus 
on other endpoints, in addition to survival and adverse events, and test ways to compensate 
for the health disadvantages that appear to occur in older patients with more limited social 
support.
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Social support remained stable over time, as indicated by mean values of MOS scores. The 
slight dip at 18 months was not statistically significant. Of note, the y-axis has been 
condensed.
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Median age, in years (range) 72 (65, 90)
Study arm
 cyclophosphamide/methotrexate/5-fluorouracil or doxorubicin/cyclophosphamide 171 (52)
 capecitabine 160 (48)
Marital status
 Married 179 (55)
 Not married 146 (45)
Cohabitation
 With at least one person 210 (65)
 Alone 115 (35)
Size of support group
 0-10 people 145 (46)
 11-25 people 110 (35)
 26+ people 58 (19)
Emotional/informational support score, median (range) 94 (3.1, 100)
Tangible support score, median (range) 94 (0, 100)
Social interaction support score, median (range) 96 (0, 100)
Affectionate support score, median (range) 100 (8.3, 100)
*
Numbers in parentheses refer to percentages unless otherwise specified.
**
Missing response data account for a sum of less than 331 at times.
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Table 2
Social Support and Tumor Size
TUMOR SIZE 1-2 centimeters > 2-5 centimeters >5 centimeters P-VALUE*
size of social support group
 0-10 58 (40) 79 (55) 7 (5) 0.887
 11-25 50 (45) 55 (50) 5 (5)
 26+ 24 (41) 30 (52) 4 (7)
Living status
 alone 39 (34) 69 (60) 7 (6) 0.053
 not alone 100 (48) 99 (47) 10 (5)
Marital status
 married 88 (49) 85 (48) 5 (3) 0.008
 not married 51 (35) 83 (57) 12 (8)
Emotional/informational support (mean (SD)) 86 (19) 84 (20) 85 (18) 0.52
Tangible support (mean (SD)) 85 (21) 80 (24) 88 915) 0.16
Social interaction support (mean (SD)) 87 (19) 82 (22) 89 (18) 0.10
Affectionate support (mean (SD)) 91 (18) 90 (18) 90 (18) 0.4
*
Chi square test or Kruskall Wallis used for analyses as appropriate.
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Table 3
Social Support and Survival
SOCIAL SUPPORT MEASURE HAZARD RATIO (95% 
confidence interval)
P-VALUE ADJUSTED* HAZARD RATIO 
(95% confidence interval)
P-VALUE
size of social support group
 0-10 versus 26+ 1.53 (0.90, 2.61) 0.12 1.30 (0.75, 2.23) 0.35
 11-25 versus 26+ 0.95 (0.53, 1.69) 0.95 0.87 (0.48, 1.57) 0.63
Living status
 alone versus not 1.49 (1.01, 2.20) 0.04 1.25 (0.85, 1.86) 0.26
Marital status
 married versus not 0.69 (0.47, 1.00) 0.05 0.84 (0.57, 1.26) 0.40
Emotional/informational support 1.02 (0.68, 1.52) 0.92 1.00 (0.66, 1.50) 0.99
Tangible support 0.98 (0.66, 1.45) 0.91 1.07 (0.72, 1.59) 0.75
Social interaction support 0.79 (0.54, 1.16) 0.23 0.80 (0.54, 1.20) 0.28
Affectionate support 0.97 (0.65, 1.43) 0.87 0.95 (0.64, 1.42) 0.81
*
In the multivariate analyses, adjustments were made for tumor burden (a function of tumor size and lymph node status) and number of tumor-
positive nodes.
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Table 4
Social Support and Severe Adverse Events
SOCIAL SUPPORT MEASURE** SEVERE ADVERSE EVENT NO SEVERE 
ADVERSE EVENT
P-VALUE*
size of social support group
 0-10 75 (52) 70 (48)
 11-25 67 (61) 43 (39) 0.230
 26+ 36 (62) 22 (38)
Living status
 alone 61 (53) 54 (47) 0.225
 not alone 126 (60) 84 (40)
Marital status
 married 106 (59) 73 (41) 0.498
 not married 81 (56) 65 (45)
Emotional/informational support (mean (standard deviation 
(SD)))
84(19) 86 (18) 0.466
Tangible support (mean (SD)) 83 (22) 83 (23) 0.976
Social interaction support (mean (SD)) 85 (22) 85 (20) 0.666




Missing response data account for a sum of less than 331 at times.
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